Sirturo® (bedaquiline) – Expanded indication
August 9, 2019 - Janssen announced the FDA approval of Sirturo (bedaquiline), as part of combination therapy in the treatment of adult and pediatric patients (12 to less than 18 years of age and weighing at least 30 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB).
Top